Clinical Trials Directory

Phase II, Randomized, Double-blind, Placebo-controlled Study of Nitazoxanide in Combination With Peginterferon Alfa-2a and Ribavirin in Patients With Hepatitis C Who Have Failed to Respond to a Prior Course of Peginterferon and Ribavirin

The purpose of this study is to determine if nitazoxanide in combination with peginterferon alfa-2a and ribavirin is safe and effective in treating chronic hepatitis C in patients that have previously failed to respond to treatment with peginterferon and ribavirin.

Stanford is not currently accepting new patients for this trial. You may want to check to see if other locations are recruiting.



  • biological : Peginterferon alfa-2a
  • drug : nitazoxanide
  • drug : Ribavirin
  • drug : Placebo

Phase: Phase 2


Ages Eligible For Study:

18 Years - N/A

Inclusion Criteria

- Chronic hepatitis C genotype 1. - Failed to respond to ?12 weeks of peginterferon and ribavirin (<2 log10 drop in Hepatitis C Virus Ribonucleic Acid (HCV RNA) at week 12 or detectable Hepatitis C Virus Ribonucleic Acid (HCV RNA) at week 24).

External Links

Contact information

Stanford University
School of Medicine
300 Pasteur Drive
Stanford, CA 94305
Shawna Thunen
Not Recruiting

Footer Links: